Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillaume Charpentier

Showing results (11-20 of 112) with videos related to

Pageof 12
Sort By:
Diabetes Care|January 12, 2021
Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-upCoralie Amadou, Sylvia Franc, Pierre-Yves Benhamou, et al.
Clinical Therapeutics|December 13, 2006
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetesAthena Philis-Tsimikas, Guillaume Charpentier, Per Clauson, et al.
Advances in Therapy|February 1, 2017
Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing StudyLuc Martinez, Alfred Penfornis, Jean-Francois Gautier, et al.
Diabetes Technology & Therapeutics|April 5, 2011
Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trialArianne C van Bon, Bruce W Bode, Caroline Sert-Langeron, et al.
BMC Medical Genetics|February 17, 2009
Evaluating the association of common APOA2 variants with type 2 diabetesKonsta Duesing, Guillaume Charpentier, Michel Marre, et al.
BMC Medical Genetics|March 4, 2008
Evaluating the association of common PBX1 variants with type 2 diabetesKonsta Duesing, Guillaume Charpentier, Michel Marre, et al.
Advances in Therapy|October 2, 2015
Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing StudyJean-Francois Gautier, Luc Martinez, Alfred Penfornis, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Increasing the safety of unannounced meal detection for artificial pancreas closed-loop with patient's hourly meal scheduleEmma Villeneuve, Sylvain Lachal, Chesner Desir, et al.
Journal of Diabetes Science and Technology|January 17, 2019
A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 DiabetesMelanie Davies, Steve Bain, Guillaume Charpentier, et al.
Diabetes|April 24, 2008
Evaluation of the association of IGF2BP2 variants with type 2 diabetes in French CaucasiansKonsta Duesing, Ghazaleh Fatemifar, Guillaume Charpentier, et al.
Pageof 12

Showing results (11-20 of 112) with videos related to

Sort By:
Pageof 12
Diabetes Care|January 12, 2021
Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-upCoralie Amadou, Sylvia Franc, Pierre-Yves Benhamou, et al.
Clinical Therapeutics|December 13, 2006
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetesAthena Philis-Tsimikas, Guillaume Charpentier, Per Clauson, et al.
Advances in Therapy|February 1, 2017
Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing StudyLuc Martinez, Alfred Penfornis, Jean-Francois Gautier, et al.
Diabetes Technology & Therapeutics|April 5, 2011
Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trialArianne C van Bon, Bruce W Bode, Caroline Sert-Langeron, et al.
BMC Medical Genetics|February 17, 2009
Evaluating the association of common APOA2 variants with type 2 diabetesKonsta Duesing, Guillaume Charpentier, Michel Marre, et al.
BMC Medical Genetics|March 4, 2008
Evaluating the association of common PBX1 variants with type 2 diabetesKonsta Duesing, Guillaume Charpentier, Michel Marre, et al.
Advances in Therapy|October 2, 2015
Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing StudyJean-Francois Gautier, Luc Martinez, Alfred Penfornis, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Increasing the safety of unannounced meal detection for artificial pancreas closed-loop with patient's hourly meal scheduleEmma Villeneuve, Sylvain Lachal, Chesner Desir, et al.
Journal of Diabetes Science and Technology|January 17, 2019
A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 DiabetesMelanie Davies, Steve Bain, Guillaume Charpentier, et al.
Diabetes|April 24, 2008
Evaluation of the association of IGF2BP2 variants with type 2 diabetes in French CaucasiansKonsta Duesing, Ghazaleh Fatemifar, Guillaume Charpentier, et al.
Pageof 12